Estimates of toxicokinetic parameters in humans for individual xenobiotics may be attained either through interspecies allometric scaling (1, 2) or through physiologically based pharmacokinetic (PBPK) modeling (3), which ultimately must invoke an interspecies scale-up as well, at least for data elicited exclusively from an animal model (4) . In allometric scaling, kinetic variables such as volume of distribution and half-life are scaled based on the assumption that they are proportional to a power of body weight, and xenobiotic clearance is additionally factored by the species' life span (5) .
Interspecies scaling as it relates to dosimetry centers on adjustments based on species mass (i.e., body weight), though some prefer that adjustments from one species to another take account of body surface area rather than body weight. For example, the U.S. Environmental Protection Agency suggests that doses be scaled from rats to humans on the basis of the ratio of human body weight to rat body weight (BW) raised to the 0.667 power, as follows (6): Dosehuman = Doserat (BWhuma*/BWrat)0667 (1) Recent proposals suggest that the exponent used should be 0.75 (7) rather than 0.667, and this value appears to be justifiable on the basis that basal metabolic rate is a function of mass raised to the 0.75 power as shown (8) :
Basal metabolism = a M0 75 (2)
where a is a mass coefficient set at 70 kcal and M is mass in kilograms. Related parameters that scale to BW0_75 include alveolar ventilation, cardiac output, renal clearance, and oxygen consumption (9) . Most often, the allometric scaling of kinetic variables is undertaken on a case-by-case basis (i.e., xenobiotic by xenobiotic), with kinetic parameters for individual xenobiotics evaluated in each of multiple species (10 (4) where ai depends on both the parameter cc and the individual errors, e,. Thus, the variability of the actual human parameter value is proportional to the rat value raised to the power b.
Results of the regression analysis from S-Plus are given in Table 1 The validity of the regression equations was confirmed as follows: for the half-life data, the regression equation along with the prediction intervals was computed using a subset of the data originally obtained (i.e., all but 18 of the data points ultimately used). The additional 18 data points (these are marked with footnote a in the data listings in the appendix) obtained later were compared to the regression results with these points excluded. These points followed basically the same pattern as the larger data set. Furthermore, two of these points fell outside the 80% prediction intervals (about three or four would have been expected to do so); none of these points fell outside the 90% prediction intervals (one or two would have been predicted to do so); and none fell outside the 95% prediction intervals (one or fewer would be expected). As the regression relationship thus proved to be useful in predicting human half-lives from rat half-lives, we concluded that the regression results obtained were valid. Note that the regression results in the tables and figures employ Tables 2 and 3 , which present the intervals for a wide range of rat values in numerical form.
To illustrate the use and interpretation of the information contained in these tables, consider a newly encountered substance, X, whose human half-life we desire to ascertain. Say that from a toxicokinetic study in rats, X is estimated to exhibit a half-life of 0.8 hr. lowest dose tested; 4) the sizes and ages of rats used were not uniform; 5) there was insufficient technical detail (e.g., sampling times, duration of sampling, number of subjects) to determine whether all studies from which kinetic data were gathered were structured appropriately (i.e., the goodness of the underlying data cannot be validated); 6) data for each xenobiotic were published generally without regard to chirality considerations; 7) data from a single experiment in a single sample of subjects were taken to be representative; 8) (11, 12) . However, 24 or more physiological, physicochemical, and enzyme kinetic parameters must be known for a given xenobiotic in a given animal model in order for PBPK models to accurately simulate the time course of xenobiotics in tissue compartments. Those active in the field point to the difficulty and expense associated with the development of comprehensive models (12) .
The simple model presented here allows for the prediction of body burdens of xenobiotics during chronic exposure if the exposure rate is known: As= E(1.44 xtl2) (6) where ASS is the average amount of xenobiotic in the body at steady-state and E is the exposure rate (the fraction of dose absorbed during each exposure period). Alternatively, exposure rates can be estimated from measurement of an average steadystate plasma concentration:
E= FD/t = C (V/1.44) x t112 (7) where D is the dose, F is the fraction of the dose absorbed, Vis the volume of distribution, X is the interval of exposure, and Css is the measured average steady-state concentration of the xenobiotic. To 
